Metabasis Therapeutics (MBRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Metabasis Therapeutics (MBRX)

MBRX 0.451

-4.8%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (56)	7/18/2007 12:47:26 PM
From: kenhott	Read Replies (1) of 66

A couple of semi-coherent things that I remember about MBRX. The CS-917 product has a problem with lactic acid. In the form of interaction w/metformin and also as part of the mode of action. So one would have to guess that MB07803 also might have the same problem. I believe that the partner was trying to stay away from this side effect and possibly underdosed the drug. I remember an inhibition curve which showed the active form of the drug with a long flat top and a steep sharp drop. If they dosed too low, they would have gotten little drug effect. They never did come thru with why MB07803 was a 2nd gen drug. I never understood/bought into the big secret. Pradefovir, they did something to adefovir which is a marketed drug and out popped the cancer problem. Somewhere in the back of my mind I wonder if it has something to do with the hepdirect technology. I don't think so but who knows. MB07133, the liver cancer drug, I am not so hot about. I made a day trade yesterday when it dropped into the toilet pre-market. As you pointed out, not sure what is going to get them going in 2007.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next